Online citations, reference lists, and bibliographies.

Infliximab For The Treatment Of Neuro-Behçet's Disease: A Case Series And Review Of The Literature.

N. Pipitone, I. Olivieri, A. Padula, S. D'Angelo, A. Nigro, G. Zuccoli, L. Boiardi, C. Salvarani
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction Behçet’s disease (BD) is a vasculitis in which the hallmark lesions are oral and often genital ulcers. Involvement of parenchymal central nervous system (neuro-Behçet’s) is a serious complication commonly characterized by brainstem and/or basal ganglia lesions. To date, treatment of neuro-Behçet’s remains largely empirical, and may not adequately control the disease (1). Serum tumor necrosis factor (TNF ) levels are increased in active BD (2), suggesting a role for TNF in disease pathogenesis. Clinically, significant improvement of various BD manifestations has been reported with TNF blockade (3). However, evidence for the efficacy of TNF blockers in the treatment of neuro-Behçet’s is scant. We present 8 patients with neuro-Behçet’s who responded favorably to infliximab therapy and review the relevant literature.
This paper references



This paper is referenced by
10.1007/s10875-012-9743-7
Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with Systemic lupus erythematosus and Behçets disease
T. Gheita (2012)
10.1007/s10067-011-1726-1
Infliximab for patients with neuro-Behcet's disease: case series and literature review
A. Borhani Haghighi (2011)
Neuro-Behcet's Disease Responsive to Adalimumab
Angela Byun Robinson (2010)
10.1016/B978-1-4160-6581-4.10036-6
Chapter 36 – BEHÇET DISEASE
Seza Ozen (2011)
10.1016/j.lpm.2015.04.010
Biologics in vasculitides: Where do we stand, where do we go from now?
Giulia Pazzola (2015)
10.4172/2471-9544.100112
Neuro-Behçet’s Disease: A Review of Neurological Manifestations and Its Treatment
Lívia Almeida Dutra (2016)
10.4236/IJCM.2011.24077
Efficacy of Infliximab Therapy for a Patient with Superficial Thrombophlebitis and Rheumatoid Arthritis
Masahiro Tada (2011)
10.1007/s10165-010-0332-4
An attack of acute neuro-Behçet’s disease during the course of chronic progressive neuro-Behçet’s disease: report of two cases
T. Matsui (2010)
10.1007/s10238-014-0328-z
Behçet syndrome: from pathogenesis to novel therapies
G. Mazzoccoli (2014)
10.1007/s00296-009-1362-0
Transient involvement of the cerebral cortex in a flare of Behçet’s syndrome
W. Conca (2009)
10.1007/s00415-013-7209-3
Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations
Seema Kalra (2013)
10.1016/S1634-6939(12)49774-5
Maladie de Behçet
D. Saadoun (2012)
10.4081/RR.2015.6115
Successful treatment of neuro-Behçet’s disease with infliximab: four years follow-up
Manjinder Kaur (2015)
10.1016/j.jaut.2009.02.011
Behçet's disease--a contemporary review.
D. Mendes (2009)
10.1016/J.REUMAE.2015.03.017
Pseudotumoral Behçet's Disease
Sara Alonso (2016)
10.1177/2040622314523062
Update on the therapy of Behçet disease
Zeinab Saleh (2014)
10.7861/clinmedicine.17-1-71
Behcet's disease
Jagdish R Nair (2017)
10.1007/978-88-470-5477-6_15
Pediatric Onset of Behcet Syndrome
E. D. Batu (2014)
10.1016/j.berh.2011.05.002
Behçet's syndrome and micro-organisms.
G. Hatemi (2011)
Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.
I. Olivieri (2011)
10.1007/s00296-009-1213-z
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs
A. Giardina (2009)
10.1097/BOR.0000000000000229
Management of primary and secondary central nervous system vasculitis
Carlo Salvarani (2016)
10.1016/j.autrev.2016.12.001
Central nervous system vasculitis in adults: An update.
L. Dutra (2017)
10.5772/22511
Biologic Agents for the Treatment of Systemic Vasculitis
Paolo Sfriso (2011)
Update on Behçet's Disease
J. Young (2009)
10.1016/B978-1-4377-0667-3.00012-6
7 – Philosophy, Goals, and Approaches to Medical Therapy
R. Nussenblatt (2010)
10.1016/j.jaut.2015.06.005
Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
H. Vallet (2015)
10.1016/j.jocn.2009.06.002
Acute aseptic meningitis and diffuse myelitis as the presenting features of neurological Behcet disease
Gerard Mullins (2009)
10.5692/CLINICALNEUROL.54.16
[A case of neuro-Behçet disease presenting with a longitudinal spinal cord lesion without pain].
Kenichi Sakuta (2014)
10.1179/2045772311Y.0000000050
Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab
I. Coulter (2012)
10.1016/j.semarthrit.2014.08.004
Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet.
O. Addimanda (2015)
10.1016/S1474-4422(09)70015-8
Neuro-Behçet's disease: epidemiology, clinical characteristics, and management
A. Al-araji (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar